The Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed) innovation grant funded by the National Institutes of Health (NIH) supports small business concerns (SBCs) that translate technology and therapeutic innovations from academic and other non-profit research sectors to the marketplace to advance the development of diagnostic and prevention tools or treatments for musculoskeletal, rheumatic, or skin diseases. It supports late-stage pre-clinical research and development, such as moving products towards regulatory approval for clinical testing or making the new lab technologies more practical to use in a clinical setting. It requires close collaboration between the original developers of these technologies and the SBCs. Applications are open to small businesses concerns (SBC) in the USA that are more than 50% owned by US citizens or permanent residents.
Applicants may apply for up to 300,000 USD in total costs for 1 year for Phase I projects. Applicants may apply for 2 million USD for up to 3 years.
Funding Opportunity Announcement (FOA) Number: PAR-23-032
The next applications are due January 5, 2025.